NeuMedics is a Seattle Based start-up that is developing novel therapeutics to treat and slow the progression of sight threatening complications of diabetes, such as Diabetic Macular Edema (DME). Globally, 21 million people are estimated to live with DME and every year, there are 75,000 new cases of DME in the United States alone. It is the primary cause of new incidences of blindness among adults aged 20–74 years.

Neumedics core expertise lies in our capability to reformulate known molecules with proven efficacy and safety into proprietary products for new indications.  The team has decades of drug development and clinical expertise, having come from biotech start ups, large pharma and the FDA.

Our business model has three strategically important foundational components that we expect will drive the company’s growth in the large, underserved ophthalmic disease market:

  1. Identify where the “Quality of Life” for a patient is or will be severely impaired unless treated with a more efficacious drug or in combination with already approved therapies.
  2. Identify and develop innovative compounds and products that leverages established science to disrupt the way a market operates and provides a creative and new solution to a problem.
  3. Will the drug address an unmet medical need and through the healthcare system reduce the reliance on hospitals while delivering the care patients desire.

We are guided by a management team of experienced professionals with more than 40 years of collective industry experience in executive management, drug development and regulatory approvals.  We have the proven ability to successfully manage all aspects of drug development through all phases of preclinical and clinical investigations and to transition drug candidates from investigational agents into commercial products.


William Schwieterman, M.D., CEO

Rheumatologist and board-certified internist

Previously 10+years Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA.

Expert in clinical development and regulatory compliance and responsible for the success of multiple NDA’s

Iain Duncan, COO

Expert in virtual start-ups and both national and multi-national outsourcing

Co Founder Corus Pharm, sold to Gilead in 2006

Over twenty years in small and startup pharma in executive positions and played an integral part in the success of multiple NDA filings

Extensive experience in mergers and acquisitions 

Carl Osborne, D.V.M., VP Development

Extensive Drug Development expertise involving over 350 products and numerous NDA’s

Former reviewer, toxicologist, and compliance officer at FDA

Directly involved with multiple product commercialization projects

Scientific Advisors

Mark L Nelson, Ph.D. Consulting VP Chemistry

Former founding scientist and Senior Director of Chemistry, Paratek Pharmaceuticals, Inventor of Omadacycline and Sarecycline holding 40 US and foreign patents in antibiotics and human therapeutics

Cheryl Rowe-Rendleman, M.D. Consulting VP Clinical and Regulatory Affairs

Highly experienced therapeutic area head with expertise in drug development, clinical trials, drug delivery, and medical communications and regulatory Affairs

Karl Herrup PhD,

Professor of Cell Biology and Neuroscience The Hong Kong University of Science and Technology

Sophie Bakri, M.D.,

Professor of Ophthalmology and   Director of the Vitreoretinal Surgery Fellowship at the Mayo Clinic

Business Advisors


Martin Simonetti

President and Chief Executive Officer of VLST since November 2005. Mr. Simonetti  has over two decades of executive, general and financial management, as well as Scientific expertise.